Sialic acid binding Ig like lectin 15 (SIGLEC15) is part of the Siglec family of glycan-recognition proteins. It is expressed in a subset of macrophages. This type-I transmembrane protein possesses two immunoglobulin-like domains, a transmembrane domain and a short cytoplasmic tail. The SIGLEC15 gene is localized on human chromosome 18q12.3.
Immunogen
Antibody was raised against a 15 amino acid peptide near the amino terminus of human SIGLEC15.
Biochem/physiol Actions
Sialic acid binding Ig like lectin 15 (SIGLEC15) recognizes a tumor-linked glycan structure called the sialyl-Tn (sTn) antigen. It is expressed on tumor-associated macrophages in tumor tissues. The protein acts as a signal transducer. SIGLEC15 associates with the adaptor protein DNAX activation protein of 12kDa (DAP12) and transduces a signal to spleen tyrosine kinase (Syk).
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Linkage
The action of this antibody can be blocked using blocking peptide SBP3500654.
Physical form
Supplied at 1 mg/mL in PBS with 0.02% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
American journal of cancer research, 11(5), 2291-2302 (2021-06-08)
Siglec15 is a recently characterized immunosuppressive transmembrane protein, which expresses in various types of solid tumors and promotes cancer development. Several studies reported that Siglec15 is a prognostic biomarker of cancer patients, and targeting Siglec15 may be a promising strategy
The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-? secretion from monocytes/macrophages through the DAP12-Syk pathway.
Laryngeal squamous cell carcinoma (LSCC) is the ultimate common malignant head and neck cancer with dismal prognosis. The expression pattern and clinical significance of Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) in LSCC are poorly understood. In order to lay the
International journal of molecular sciences, 24(1) (2023-01-09)
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been identified as a crucial immune suppressor in human cancers, comparable to programmed cell death 1 ligand (PD-L1). However, the regulatory mechanisms underlying its transcriptional upregulation in human cancers remain largely unknown. Here
Siglec-15: an immune system Siglec conserved throughout vertebrate evolution.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.